• Completed

NCT03288493: Phase 1/2 - P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Myeloma

Updated: Jun 15

(PRIME)

NCT03288493: Phase 1/2 - P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

P-BCMA

NCT03288493: Phase 1/2 - P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)


Phase 1 of the study is comprised of an open-label, single ascending dose (SAD), multiple cohort study; a multiple dose cycle administration cohort study; and a combination administration study of P-BCMA-101 autologous T stem cell memory (Tscm) CAR-T cells in patients with relapsed / refractory MM. Followed by a Phase 2, open-label, efficacy and safety study. Rimiducid may be administered as indicated.


Sponsor

Poseida Therapeutics, Inc.


Collaborator

California Institute for Regenerative Medicine (CIRM)

 

ClinicalTrials.gov Identifier: NCT03288493

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P BCMA-101 in Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)

First Posted : September 20, 2017


Click here for details on Clinicaltrials.gov

 

CART - BCMA : National Cancer Institute


Biological: P-BCMA-101 CAR-T cells


Drug: Rimiducid

 

Biological: P-BCMA-101 CAR-T cells

autologous anti-BCMA centyrin-based chimeric antigen receptor-expressing Tscm

autologous P-BCMA-101 CAR-T cells

autologous P-BCMA-101 CARTyrin-T cells


Drug: Rimiducid

 

134 Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: CAR T Therapies for Myeloma: Novel Approaches and Longer-Term Follow Up Data

Hematology Disease Topics & Pathways:

Biological, Therapies, CAR-Ts

Saturday, December 5, 2020: 10:45 AM

https://ash.confex.com/ash/2020/webprogram/Paper142695.html

 

- California: University of California San Diego

- California: University of California San Francisco

- Colorado: Sarah Cannon/Colorado Blood Cancer Institute Denver

- Illinois: University of Chicago

- Maryland: Johns Hopkins Baltimore

- New Jersey: Hackensack University Medical Center

- Pennsylvania: University of Pennsylvania Philadelphia

- Tennessee: Sarah Cannon Research Institute Nashville

- Texas: The University of Texas MD Anderson Cancer Center Houston

- Washington: Swedish Cancer Inst Seattle

 

Locations

United States, Arizona

United States, California

United States, Colorado

United States, Illinois

United States, Kansas

United States, Maryland

United States, Michigan

United States, New Jersey

United States, Pennsylvania

United States, Tennessee

United States, Texas

United States, Washington




Posts Archive